Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility

Previous genome-wide association studies (GWAS) have shown several risk alleles to be associated with breast cancer. However, the variants identified so far contribute to only a small proportion of disease risk. The objective of our GWAS was to identify additional novel breast cancer susceptibility variants and to replicate these findings in an independent cohort. We performed a two-stage association study in a cohort of 3,064 women from Alberta, Canada. In Stage I, we interrogated 906,600 single nucleotide polymorphisms (SNPs) on Affymetrix SNP 6.0 arrays using 348 breast cancer cases and 348 controls. We used single-locus association tests to determine statistical significance for the observed differences in allele frequencies between cases and controls. In Stage II, we attempted to replicate 35 significant markers identified in Stage I in an independent study of 1,153 cases and 1,215 controls. Genotyping of Stage II samples was done using Sequenom Mass-ARRAY iPlex platform. Six loci from four different gene regions (chromosomes 4, 5, 16 and 19) showed statistically significant differences between cases and controls in both Stage I and Stage II testing, and also in joint analysis. The identified variants were from EDNRA, ROPN1L, C16orf61 and ZNF577 gene regions. The presented joint analyses from the two-stage study design were not significant after genome-wide correction. The SNPs identified in this study may serve as potential candidate loci for breast cancer risk in a further replication study in Stage III from Alberta population or independent validation in Caucasian cohorts elsewhere.

[1]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[2]  R. Klein,et al.  Power analysis for genome-wide association studies , 2007, BMC Genetics.

[3]  R. Wilkins.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[4]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[5]  Seokjoong Kim,et al.  Tetrameric Oligomerization Mediates Transcriptional Repression by the BRCA1-dependent Kruppel-associated Box-Zinc Finger Protein ZBRK1* , 2004, Journal of Biological Chemistry.

[6]  Daniel Levy,et al.  A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study , 2007, BMC Medical Genetics.

[7]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[8]  S. Seal,et al.  A genome wide linkage search for breast cancer susceptibility genes , 2006, Genes, chromosomes & cancer.

[9]  Stephen B. Gruber,et al.  FGFR2 Is a Breast Cancer Susceptibility Gene in Jewish and Arab Israeli Populations , 2008, Cancer Epidemiology Biomarkers & Prevention.

[10]  Deborah Hughes,et al.  Genome-wide association study identifies five new breast cancer susceptibility loci , 2010, Nature Genetics.

[11]  N. Rahman,et al.  ATM and breast cancer susceptibility , 2006, Oncogene.

[12]  Patrick O. Brown,et al.  Gene Expression Patterns in Pancreatic Tumors, Cells and Tissues , 2007, PloS one.

[13]  Nilanjan Chatterjee,et al.  Estimation of effect size distribution from genome-wide association studies and implications for future discoveries , 2010, Nature Genetics.

[14]  D. Gudbjartsson,et al.  Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer , 2007, Nature Genetics.

[15]  Liuda Ziaugra,et al.  SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform , 2009, Current protocols in human genetics.

[16]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[17]  The Polish Breast Cancer Consortium.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002 .

[18]  J. Drevs,et al.  Angiogenesis and the ET-1/ETA Receptor System: Immunohistochemical Expression Analysis in Bone Metastases from Patients with Different Primary Tumors , 2004, Angiogenesis.

[19]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[20]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[21]  M. Thun,et al.  Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 , 2009, Nature Genetics.

[22]  Wen-Hwa Lee,et al.  Functional Dissection of Transcription Factor ZBRK1 Reveals Zinc Fingers with Dual Roles in DNA-binding and BRCA1-dependent Transcriptional Repression* , 2004, Journal of Biological Chemistry.

[23]  P. Gregersen,et al.  Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33 , 2008, Proceedings of the National Academy of Sciences.

[24]  C. Plass,et al.  20q11.1 amplification in giant‐cell tumor of bone: Array CGH, FISH, and association with outcome , 2006, Genes, chromosomes & cancer.

[25]  T. Rebbeck,et al.  Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. , 2008, Carcinogenesis.

[26]  G. Abecasis,et al.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.

[27]  Catherine Charbonnel,et al.  Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen , 2008, Breast Cancer Research and Treatment.

[28]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[29]  M. King,et al.  Linkage of early-onset familial breast cancer to chromosome 17q21. , 1990, Science.

[30]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[31]  A. Sigurdsson,et al.  Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer , 2008, Nature Genetics.

[32]  P. Visscher,et al.  Common SNPs explain a large proportion of heritability for human height , 2011 .

[33]  W. Willett,et al.  A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.

[34]  P. Natali,et al.  Role of endothelin-1 in neovascularization of ovarian carcinoma. , 2000, The American journal of pathology.

[35]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.